Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan

Abstract Background and Aim The aim of the present study was to examine the lifestyle‐ and comorbidity‐related determinant factors of the prescription of proton pump inhibitors (PPIs) for patients in whom Helicobacter pylori has been eradicated, and to evaluate the relationship between PPI prescript...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Furitsu Shimada, Hiroyoshi Endo, Ayako Takamori, Takuya Matsunaga, Shun Fujimoto, Shimpei Shirai, Toshihiko Kakiuchi, Takashi Akutagawa, Yasuhisa Sakata, Koichi Node, Kohei Yamanouchi, Shotaro Nakamura, Kazuma Fujimoto, Motohiro Esaki
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	aging clinical symptoms hypertension potassium‐competitive acid blocker reflux esophagitis Diseases of the digestive system. Gastroenterology RC799-869
Accès en ligne:	https://doaj.org/article/0b8e4b7e99e84179909d04c95e4fb58d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:0b8e4b7e99e84179909d04c95e4fb58d
record_format	dspace
spelling	oai:doaj.org-article:0b8e4b7e99e84179909d04c95e4fb58d2021-11-18T11:25:44ZLifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan2397-907010.1002/jgh3.12666https://doaj.org/article/0b8e4b7e99e84179909d04c95e4fb58d2021-11-01T00:00:00Zhttps://doi.org/10.1002/jgh3.12666https://doaj.org/toc/2397-9070Abstract Background and Aim The aim of the present study was to examine the lifestyle‐ and comorbidity‐related determinant factors of the prescription of proton pump inhibitors (PPIs) for patients in whom Helicobacter pylori has been eradicated, and to evaluate the relationship between PPI prescription and the severity of endoscopic esophagitis. Methods This retrospective study included patients who underwent H. pylori eradication from May 2012 to September 2016 at Saiseikai Karatsu Hospital. All patients received upper gastrointestinal endoscopy before H. pylori eradication. Patients with open peptic ulcers and/or malignant diseases were excluded, and a final total of 389 patients were evaluated. Medical records were reviewed to determine the prescription of PPIs after H. pylori eradication, lifestyle‐related factors, and comorbidities. Lifestyle‐related factors were confirmed by a questionnaire. Results PPIs were administered to 124 of 389 patients (31.9%). The only lifestyle‐related risk factor for the prescription of PPIs after H. pylori eradication was older age (P < 0.01). Hypertension increased the prescription of PPIs (P = 0.034). The prescription of PPIs was not influenced by the presence of grade A esophagitis, whereas the PPI prescription rate was significantly increased in patients with grades B/C/D endoscopic esophagitis (P < 0.01). The grade of chronic gastritis before H. pylori eradication had no effect on the prescription of PPIs. Conclusion The lifestyle‐ and comorbidity‐related risk factors for the prescription of PPIs after H. pylori eradication were older age and hypertension, while mild endoscopic esophagitis had no influence on PPI prescription.Furitsu ShimadaHiroyoshi EndoAyako TakamoriTakuya MatsunagaShun FujimotoShimpei ShiraiToshihiko KakiuchiTakashi AkutagawaYasuhisa SakataKoichi NodeKohei YamanouchiShotaro NakamuraKazuma FujimotoMotohiro EsakiWileyarticleagingclinical symptomshypertensionpotassium‐competitive acid blockerreflux esophagitisDiseases of the digestive system. GastroenterologyRC799-869ENJGH Open, Vol 5, Iss 11, Pp 1284-1288 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	aging clinical symptoms hypertension potassium‐competitive acid blocker reflux esophagitis Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	aging clinical symptoms hypertension potassium‐competitive acid blocker reflux esophagitis Diseases of the digestive system. Gastroenterology RC799-869 Furitsu Shimada Hiroyoshi Endo Ayako Takamori Takuya Matsunaga Shun Fujimoto Shimpei Shirai Toshihiko Kakiuchi Takashi Akutagawa Yasuhisa Sakata Koichi Node Kohei Yamanouchi Shotaro Nakamura Kazuma Fujimoto Motohiro Esaki Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
description	Abstract Background and Aim The aim of the present study was to examine the lifestyle‐ and comorbidity‐related determinant factors of the prescription of proton pump inhibitors (PPIs) for patients in whom Helicobacter pylori has been eradicated, and to evaluate the relationship between PPI prescription and the severity of endoscopic esophagitis. Methods This retrospective study included patients who underwent H. pylori eradication from May 2012 to September 2016 at Saiseikai Karatsu Hospital. All patients received upper gastrointestinal endoscopy before H. pylori eradication. Patients with open peptic ulcers and/or malignant diseases were excluded, and a final total of 389 patients were evaluated. Medical records were reviewed to determine the prescription of PPIs after H. pylori eradication, lifestyle‐related factors, and comorbidities. Lifestyle‐related factors were confirmed by a questionnaire. Results PPIs were administered to 124 of 389 patients (31.9%). The only lifestyle‐related risk factor for the prescription of PPIs after H. pylori eradication was older age (P < 0.01). Hypertension increased the prescription of PPIs (P = 0.034). The prescription of PPIs was not influenced by the presence of grade A esophagitis, whereas the PPI prescription rate was significantly increased in patients with grades B/C/D endoscopic esophagitis (P < 0.01). The grade of chronic gastritis before H. pylori eradication had no effect on the prescription of PPIs. Conclusion The lifestyle‐ and comorbidity‐related risk factors for the prescription of PPIs after H. pylori eradication were older age and hypertension, while mild endoscopic esophagitis had no influence on PPI prescription.
format	article
author	Furitsu Shimada Hiroyoshi Endo Ayako Takamori Takuya Matsunaga Shun Fujimoto Shimpei Shirai Toshihiko Kakiuchi Takashi Akutagawa Yasuhisa Sakata Koichi Node Kohei Yamanouchi Shotaro Nakamura Kazuma Fujimoto Motohiro Esaki
author_facet	Furitsu Shimada Hiroyoshi Endo Ayako Takamori Takuya Matsunaga Shun Fujimoto Shimpei Shirai Toshihiko Kakiuchi Takashi Akutagawa Yasuhisa Sakata Koichi Node Kohei Yamanouchi Shotaro Nakamura Kazuma Fujimoto Motohiro Esaki
author_sort	Furitsu Shimada
title	Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
title_short	Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
title_full	Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
title_fullStr	Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
title_full_unstemmed	Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan
title_sort	lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after helicobacter pylori eradication in japan
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/0b8e4b7e99e84179909d04c95e4fb58d
work_keys_str_mv	AT furitsushimada lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT hiroyoshiendo lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT ayakotakamori lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT takuyamatsunaga lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT shunfujimoto lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT shimpeishirai lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT toshihikokakiuchi lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT takashiakutagawa lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT yasuhisasakata lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT koichinode lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT koheiyamanouchi lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT shotaronakamura lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT kazumafujimoto lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan AT motohiroesaki lifestyleandcomorbidityrelatedfactorsfortheprescriptionofprotonpumpinhibitorsafterhelicobacterpylorieradicationinjapan
_version_	1718420826978516992

Lifestyle‐ and comorbidity‐related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan

Documents similaires